BioSpace News Archive

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced additional data from two pivotal clinical studies demonstrating sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure compared to an active comparator, suggesting long-term benefits in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).

Cue Biopharma, Inc. (Nasdaq: CUE) announced today the presentation of new positive data from its ongoing fully enrolled Phase 1 trials evaluating its lead interleukin-2 (IL-2)-based T cell engager, CUE-101, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for patients with recurrent/metastatic HPV+ head and neck squamous cell carcinoma (HNSCC).

MiNK Therapeutics, Inc. (NASDAQ: INKT) today presented new agenT-797 data in solid tumor cancers at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”) today presented a poster at the annual meeting of the Society for Immunotherapy of Cancer (SITC), indicating the Company’s ICE® improves cytotoxicity of NK and CAR-NK cells and that NK cells redirected by ICE® exhibit at least the same efficacy against tumor cells as CAR-NK cells alone or redirected by the ICE®.

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting™ will be held November 10-14, 2023, in Boston, Mass.

Florida Cancer Specialists & Research Institute physicians will present at the Society for Immunotherapy of Cancer Annual Meeting this week in San Diego.

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will be presenting in fireside chats at two upcoming investor conferences.

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA.

BioStem Technologies Inc. announces that it has closed an oversubscribed private placement of common stock to accredited investors for an aggregate of 1,337,000 units at a price of $1.50 per Unit for gross proceeds of $2 million.

Oncocyte Corporation, a precision diagnostics company, announced that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights.